Caroline Robert

Research interests

Publications

• Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.10.001

• Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet · 2020 · 10.1016/s0140-6736(20)30934-x

• A decade of immune-checkpoint inhibitors in cancer therapy

  Nature Communications · 2020 · 10.1038/s41467-020-17670-y

• Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1904059

• Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(19)30388-2

• Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(19)30274-8

• Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

  Annals of Oncology · 2019 · https://doi.org/10.1093/annonc/mdz011

• Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

  New England Journal of Medicine · 2018 · 10.1056/nejmoa1802357

• Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

  The Lancet Oncology · 2018 · 10.1016/s1470-2045(18)30142-6

• Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2017 · 10.1093/annonc/mdx225

• Adjuvant Dabrafenib plus Trametinib in Stage III BRAF -Mutated Melanoma

  New England Journal of Medicine · 2017 · 10.1056/nejmoa1708539

• Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

  Annals of Oncology · 2017 · 10.1093/annonc/mdx176

• Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

  Annals of Oncology · 2017 · 10.1093/annonc/mdx108

• Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

  JAMA · 2016 · 10.1001/jama.2016.4059

• Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

  Journal of Clinical Oncology · 2016 · 10.1200/jco.2015.64.0391

• Immune-related adverse events with immune checkpoint blockade: a comprehensive review

  European Journal of Cancer · 2016 · 10.1016/j.ejca.2015.11.016

• Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

  New England Journal of Medicine · 2016 · 10.1056/nejmoa1611299

• Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma

  Journal of Clinical Oncology · 2016 · 10.1200/jco.2016.67.2477

• Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)70122-1

• Pembrolizumab versus Ipilimumab in Advanced Melanoma

  New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1503093

• Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

  Science · 2015 · 10.1126/science.aad1329

• Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

  New England Journal of Medicine · 2015 · 10.1056/nejmoa1414428

• Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

  Journal of Clinical Oncology · 2015 · 10.1200/jco.2014.56.2736

• Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)00083-2

• Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

  The Lancet · 2015 · 10.1016/s0140-6736(15)60898-4

• Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

  The Lancet Oncology · 2014 · 10.1016/s1470-2045(14)70012-9

• PD-1 blockade induces responses by inhibiting adaptive immune resistance

  Nature · 2014 · https://doi.org/10.1038/nature13954

• Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

  Nature · 2014 · 10.1038/nature13121

• Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

  New England Journal of Medicine · 2014 · 10.1056/nejmoa1412690

• Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

  New England Journal of Medicine · 2014 · 10.1056/nejmoa1406037

• Nivolumab in Previously Untreated Melanoma without BRAF Mutation

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1412082

• Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

  The Lancet · 2014 · 10.1016/s0140-6736(14)60958-2

• Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

  New England Journal of Medicine · 2013 · 10.1056/nejmoa1305133

• Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

  The Lancet Oncology · 2012 · 10.1016/s1470-2045(12)70431-x

• Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

  Zurich Open Repository and Archive (University of Zurich) · 2012 · 10.5167/uzh-63198

• Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

  New England Journal of Medicine · 2012 · 10.1056/nejmoa1203421

• Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

  New England Journal of Medicine · 2011 · 10.1056/nejmoa1104621

• Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

  New England Journal of Medicine · 2011 · https://doi.org/10.1056/nejmoa1103782

• Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

  New England Journal of Medicine · 2010 · https://doi.org/10.1056/nejmoa1003466

• CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner

  The Journal of Experimental Medicine · 2005 · 10.1084/jem.20051511

• Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial

  Journal of Translational Medicine · 2005 · 10.1186/1479-5876-3-10

Current projects

No projects listed.